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Abstract
Background: Accumulating evidence suggests that the brain’s nitric oxide (NO) signalling system may be involved
in the pathophysiology of schizophrenia and could thus constitute a novel treatment target. The study was
designed to investigate the benefit of L-lysine, an amino acid that interferes with NO production, as an add-on
treatment for schizophrenia.
Methods: L-lysine, 6 g/day, was administered to 10 patients with schizophrenia as an adjunctive to their
conventional antipsychotic medication. The study was designed as a single-blinded, cross-over study where
patients were randomly assigned to initial treatment with either L-lysine or placebo and screened at baseline, after
four weeks when treatment was crossed over, and after eight weeks.
Results: L-lysine treatment caused a significant increase in blood concentration of L-lysine and was well tolerated.
A significant decrease in positive symptom severity, measured by the Positive And Negative Syndrome Scale
(PANSS), was detected. A certain decrease in score was also observed during placebo treatment and the effects on
PANSS could not unequivocally be assigned to the L-lysine treatment. Furthermore, performance on the Wisconsin
Card Sorting Test was significantly improved compared to baseline, an effect probably biased by training.
Subjective reports from three of the patients indicated decreased symptom severity and enhanced cognitive
functioning.
Conclusions: Four-week L-lysine treatment of 6 g/day caused a significant increase in blood concentration of
L-lysine that was well tolerated. Patients showed a significant decrease in positive symptoms as assessed by PANSS
in addition to self-reported symptom improvement by three patients. The NO-signalling pathway is an interesting,
potentially new treatment target for schizophrenia; however, the effects of L-lysine need further evaluation to
decide the amino acid’s potentially beneficial effects on symptom severity in schizophrenia.
Trial registration NCT00996242
Background
Schizophrenia is a severely debilitating brain disorder
that poses a serious healthcare problem worldwide.
Available antipsychotics show efficacy in alleviating psy-
chotic symptoms. However, negative symptoms and the
cognitive deficits are to a large extent resistant to anti-
psychotic treatment [1,2]. Thus, there is a need to find
new treatment strategies to improve the treatment of
these symptoms and deficits. One such candidate target
for novel treatments may be the nitric oxide (NO)
signalling system of the brain. As such, translational
evidence for this contention can be derived from the
observations that methylene blue, which blocks NO-
dependent soluble guanylate cyclase-mediated intracellu-
lar signalling, was shown to exert therapeutic effects as
an adjuvant to established antipsychotics in the treat-
ment for schizophrenia in humans [3]. In addition, a
more recent study showed that methylene blue
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(PCP), induced behavioural alterations in mice [4].
Despite that the principle mechanism of action of PCP
is glutamatergic N-methyl D-aspartate (NMDA) recep-
tor antagonism, PCP has secondary effects on several
other neurotransmitter systems (see, for example, [5]) as
well as on NO-signalling [6]. Furthermore, the inducible
NO synthase inhibitor, minocycline, was recently sug-
gested to have beneficial effects as an add-on treatment
in patients with schizophrenia [7,8]. Thus, accumulating
evidence indicates that alterations in NO function may
be involved in the pathophysiology of schizophrenia and
these original findings motivate further investigations of
the potential utility of NO modulation as a novel phar-
macological treatment rationale for schizophrenia (for
review, see [9]).
Preclinical findings supporting a “NO dysregulation
hypothesis for schizophrenia”
To better understand the underlying pathophysiology of
schizophrenia, several methods have been developed to
model schizophrenia in humans and experimental ani-
mals. To this end, pharmacological challenge with PCP
has been shown to produce a psychotic condition in
humans that includes all major symptoms of schizophre-
nia. Thus, the “PCP model of schizophrenia” has proved
to be an important tool for increasing our understand-
ing of the disorder and is considered to have significant
heuristic value in the development of novel therapeutic
treatment strategies [10].
Interestingly, our preclinical studies have shown that
pre-treatment with NO synthase (NOS) inhibitors effec-
tively block the disruptive effect of PCP on behaviours
involving several cognitive domains such as pre-attentive
information processing, non-associative learning, selec-
tive attention, cognitive flexibility, working and long-
term memory, as well as deficits in social interaction in
rodents [11-20]. These observations suggest that inhibi-
tion of NOS is able to counteract very complex beha-
vioural effects of PCP.
Inhibition of NO production by L-lysine: A new treatment
option for patients with schizophrenia?
NO is produced from the amino acid L-arginine and
molecular oxygen in a chemical reaction catalyzed by
NOS. Interestingly, the essential amino acids L-lysine
and L-arginine share a highly specific membrane bound
transport system, the cationic amino acid transporter
[21]. This transport system seems critical in mediating
the influx of L-arginine across the blood-brain barrier
[22]. Furthermore, in vitro studies have shown that
saturation of the transporter with L-lysine inhibits trans-
port of L-arginine, depletes intra-cellular stores of
L-arginine [23], and reduces NO production [24].
As noted above, our previous findings suggest that the
schizophrenia-like behavioural effects of PCP in experi-
mental animals can be ameliorated by pre-treatment
with a NOS inhibitor. In analogy it may be speculated
that inhibition of L-arginine transport by L-lysine treat-
ment would decrease NO levels and, thereby, attenuate
PCP-induced behavioural effects. In support of this
argument we recently showed that sub-chronic
pre-treatment with L-lysine ameliorates PCP-induced
disruption of prepulse inhibition, a measure of pre-
attentive information processing, in mice in a dose-
related manner without affecting basal prepulse inhibi-
tion [25]. Moreover, using a NO selective microsensor
and in vivo voltammetry in awake freely moving rats, we
recently found that acute L-lysine administration
decreased NO levels in the rat prefrontal cortex [26]. A
competitive antagonism of L-arginine transport across
the blood-brain barrier and a depletion of L-arginine
supply for NO synthesis may explain these findings. A
relative lack of substrate for NO production would pre-
vent a hypothesized PCP-induced increase in NO levels
and thus the disruptive effect of PCP on cognitive
function.
The aim of the present study was to investigate the
relevance of these contentions in humans. To this end,
the effect of adjunctive L-lysine treatment on symptom
severity and cognition was studied in patients with schi-
zophrenia. Ten patients with a diagnosis of schizophre-
nia were treated with L-lysine, 6 grams daily, or placebo
for four weeks in a cross-over design. Outcome mea-
sures were assessed at baseline, after four weeks and
after eight weeks.
Methods
Subjects
Eleven well-defined psychiatric outpatients were
recruited from the following three clinics: Nå-Ut Tea-
met, Psykosteamet Järntorget, and Psykosvård i Väster,
the Sahlgrenska University Hospital, Gothenburg, Swe-
den. Inclusion criteria consisted of a DSM-IV diagnosis
of schizophrenia (F295.xx) and that the patient had been
in a stable phase of illness (that is, no psychotic episode)
during the last two months preceding study participa-
tion. Furthermore, all subjects were required to be on a
stable dose of antipsychotic medication, in addition to
any other prescribed medication, for at least three
months before the start of the study (for specification of
prescribed antipsychotic drugs, see Table 1). No major
medical or neurological conditions or other psychiatric
diagnosis (besides DSM-IV, F295.xx) were allowed as
assessed by a comprehensive medical history and a med-
ical examination. Furthermore, all subjects had to show
normal admission laboratory tests and vital signs.
Substance abuse, apart from smoking, was grounds for
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Medical Products Agency and the Internal Review
Board at the University of Gothenburg, Sweden. One
participant (subject number 9) terminated participation
after four weeks of treatment due to non-compliance
with the drug administration procedure, thus resulting
in a total of 10 patients completing the study.
Demographic data
The demographic data of the patients enrolled in the
present study are shown in Table 1.
Study design
The study was designed as a single-blinded, placebo-
controlled, eight-week cross-over study. A written con-
sent was signed before patients entered the study and
were randomly assigned to initial treatment with either
L-lysine dissolved in a soft drink or a soft drink only
(the placebo) and screened for the outcome measures at
baseline, after 28 days of treatment when treatment was
crossed over, and after 56 days when treatment was
terminated.
Study compound
L-lysine is a basic amino acid (that is, it carries a posi-
tive net charge at physiological pH) with a high nutri-
tional value. It is readily absorbed from the intestine
and metabolized by the liver. High levels of L-lysine are
found in muscle, and increased intake of L-lysine is
more readily distributed to this compartment than to,
for example, blood. L-lysine supplementation has been
tried as treatment for, for example, recurrent herpes
simplex infection [27] and osteoporosis [28]. It is an
essential amino acid and has very good oral bioavailabil-
ity [29] and brain penetration [22]. L-lysine monohy-
drochloride is soluble in water and has a mild salty
flavour. In the present study the compound was mixed
with juice or a soft drink and ingested once a day. The
dose of L-lysine was set to 6 g/day, a dose above dietary
levels (dietary intake of L-lysine rich foods may reach 3
g/day) but within known safety limits [30]. L-lysine
monohydrochloride was synthesized by Apoteket Pro-
duktion & Laboratorier, APL Stockholm.
Safety aspects
The only reported adverse effects of L-lysine treatment in
humans are transient gastrointestinal problems in a few
subjects. Based on published studies, a long-term addi-
tion of 6 g of L-lysine to the daily diet should be
safe [30]. In short-term human studies doses as high as
40 g/day have been tested and again the only reported
adverse effects were abdominal cramps and transient
diarrhoea that resolved as the dose was decreased
[31,32]. Toxicological studies in rats indicate that the
lethal dose 50 (LD50) of intravenous L-lysine is 4 mg/kg
[33]. No lethal dosage could be reached by oral adminis-
tration. Long-term studies on L-lysine administration
(up to two years) have not revealed any adverse effects [30].
Clinical assessments
Patients were screened for outcome measures at base-
line, after four weeks, and after eight weeks. Symptom
severity and functional outcome was assessed with the
PANSS, and the UKU-Scale for monitoring side effects
of psychiatric medication. Measures of physical status
included blood sample analysis for L-lysine concentra-
tion and amino acid composition, blood pressure, preg-
nancy test and weight, all obtained by a trained research
psychiatrist. Tests of cognitive performance included the
Ray Auditory Verbal Learning Test (RAVLT), Continu-
ous Performance Test (CPT; vigilance and attention),
Trail Making Test A and B (speed of processing), Letter
and Number Span test (working memory) and Wiscon-
sin Card Sorting Test (WCST; working memory and
executive functioning). All tests were carried out by a
trained behavioural scientist.
Table 1 Demographic data from all patients participating in the study
Case Age (years) Sex Subtype (DSM-IV) Duration of illness (years) Antipsychotic treatment, dosage
1 56 M Schizophrenia, undifferentiated 9 Risperdal consta 25 mg/2w
2 23 F Schizophrenia, undifferentiated 3 Leponex 700 mg/day,
3 29 M Schizophrenia, unspecified 8 Risperdal 2 mg/day, Abilify 25 mg/day
4 45 M Schizophrenia, paranoid 6 NA
5 35 M Schizophrenia, unspecified 11 Leponex 200 mg/day, Abilify 15 mg/day
6 54 M Schizophrenia, undifferentiated 29 Zyprexa 15 mg/day
7 51 M Schizophrenia, paranoid 23 Leponex 100 mg/day, Abilify 10 mg/day
8 56 M Schizophrenia, undifferentiated > 15 Zyprexa 10 mg/day, Cisordinol 140 mg inj 1/4w
9-- - - -
10 39 F Schizophrenia, paranoid 8 Risperdal 4 mg/day
11 44 M Schizophrenia, unspecified 26 Leponex 800 mg/day, Abilify 10 mg/day
Case 9 dropped out due to difficulties ingesting the study medicine.
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Blood samples (4 ml) for assessment of essential amino
acid profiling were obtained at baseline after L-lysine treat-
ment, and after placebo treatment. The blood samples
were sent to the Laboratory for Clinical Chemistry, the
Sahlgrenska University Hospital, Gothenburg, Sweden, for
analysis using a ninhydrin reagent for photometric deter-
mination of amino acids (for procedure, see [34]).
Statistics
Statistical analysis was performed by one- or two-way
ANOVA when appropriate and multiple testing was
subjected to Bonferroni correction with the significance
level set to 0.05. Linear regression analysis was also per-
formed to test if blood level of L-lysine concentration
could predict functional outcome of any of the outcome
measures collected.
Results
L-lysine treatment significantly increased blood
concentration of L-lysine without inducing adverse side
effects
Analysis of L-lysine concentration in blood showed a
significant effect of treatment such that concentration
increased after L-lysine treatment (6 g/day for four
weeks) compared to baseline and placebo levels (F(2,14)
= 7.84, P < 0.05, Table 2), in 8 out of the 10 patients.
T w op a t i e n t ss h o w e dn oc h a n g ei nL - l y s i n ec o n c e n t r a -
tion and were treated as non-responders and included
in an “Intention to Treat” group (n = 10), which was
analyzed in parallel with the responders (n = 8) in the
statistical analysis. Furthermore, the L-lysine treatment
was not found to induce any adverse side effects includ-
ing extrapyramidal effects. Neither was L-lysine treat-
ment found to significantly alter blood concentration of
any of the other amino acids analysed, such as citrulline,
arginine, proline, glutamate and alanine.
Positive symptom scores were significantly improved
during treatment
Symptom severity as measured by the positive symp-
toms sub-scale of PANSS showed a significant decrease
(F(2,14) = 13.11, P < 0.001). This effect was mainly due
to a significant change in scores for the sub-scales asses-
sing delusions and suspiciousness/persecution. It should
be noted that the patients tended to improve their per-
formance on the positive symptoms PANSS measure
regardless of treatment, an effect that may be explained
by the increased attention the patients received simply
by taking part in the study. Since such an effect would
jeopardize the interpretation of the results, measures
were taken to control for this effect by applying a two-
way ANOVA to the data analyzing the interaction
between treatment order (L-lysine treatment during first
or second testing period) and test session (Baseline, Test
1 and Test 2). The rationale behind this approach was
that given a biologically significant effect of L-lysine, a
major part of the improvement in the testing score
should be attributed to the L-lysine treatment period,
and less to the placebo period and this effect should be
detected in the interaction analysis. Albeit close to a sig-
nificant interaction (F(2,12) = 3.08, P = 0.08), this analysis
did not reach statistical significance and consequently it
could not be excluded that a significant part of the effects
obtained on the PANSS score was caused by factors not
related to L-lysine treatment.
Problem solving capacity was significantly improved
during treatment
Problem solving capacity and cognitive flexibility, as
assessed by the WCST, was significantly improved fol-
lowing treatment. This effect was statistically significant
measured as decrease in the number of errors on the
WCST (F(2,14) = 4.91, P < 0.05, Table 2), measured as
perseverant errors (F(2,14) = 4.46, P < 0.05), and mea-
sured as perseverant answers (F(2,14) = 4.77, P <0 . 0 5 ) .
A similar tendency of the patients to improve their
WCST performance regardless of treatment was
observed. Statistical analysis did not show a significant
interaction between treatment order and test session
and consequently the effects obtained were caused by
factors not related to L-lysine treatment.
The RAVLT, CPT-IP, TRAIL MAKING A and B, and
Letter and Number Span test outcome scores were not
significantly affected by treatment.
Besides the outcome measures, patients self-reported
on their condition, most commonly once a week when
receiving the study drug. As such, no patient reported
any adverse side-effects or worsening of symptoms.
Interestingly though, three patients self-reported
improvements of their symptoms. Two patients reported
a decrease in positive symptoms, such as attenuated
auditory hallucinations (i.e. hearing voices), an improve-
ment that disappeared after trial termination. One of
these patients also experienced improved attention fol-
lowing L-lysine treatment and one other patient
reported increased mental stability and memory capacity
following L-lysine treatment, an effect that remained
several weeks after trial termination.
Discussion
Evidence was obtained suggesting that 6 g/day of
adjunctive L-lysine treatment is a sufficient dose for
increasing blood L-lysine levels above the nutritional,
naturally occurring levels, without inducing adverse
side-effects. In addition, there was a significant decrease
in the positive PANSS scores and WCST over the whole
study period. These two measures represent different
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measure psychosis severity and WCST cognitive func-
tionality. Thus, evidence was obtained for symptom
improvement in both of these domains; however,
accounts for placebo effects, such as training on WCST,
cannot be excluded.
Given the limited number of patients enrolled in the
study, difficulties arise as to the possibilities of making
reliable conclusions about the efficacy of L-lysine treat-
ment. However, it should be noted that despite the low
number of participants statistically significant effects of
treatment on outcome measures were in fact obtained.
Furthermore, albeit the relatively small changes in
PANSS and WCST scores observed, statistical analysis
showed fairly high effect sizes and observed powers for
these changes (positive PANSS (n = 10): effect size (h)=
0.76, observed power (1-b) = 0.99; WCST number of
errors (n = 10): effect size (h) = 0.64, observed power
(1-b) = 0.77) indicating that they were of significant
magnitude and detectable also in small sample sizes.
Needless to say, it is also possible that a higher dose of
L-lysine or a longer treatment period may have provided
more clear-cut results. The reason that two participants
(one male and one female) did not get an elevation in
their blood concentration of L-lysine is unknown. In
order to assess adherence to the L-lysine treatment the
L-lysine containers were carefully labelled with dates
and empty containers were collected weekly. However,
there was no control for actual intake of the study medica-
tion beyond the assessed blood L-lysine concentrations.
Metabolic individual differences, due to i.a. intense physi-
cal activity or gender, or simply non-adherence to L-lysine
treatment, cannot be ruled out as one of the contributing
factors to these findings.
Cautions should be taken when interpreting the data.
Both the PANSS and the WCST scores seemed to
improve over repeated testing, and consequently this pla-
cebo and/or training effect could explain the effects
obtained. The study design presently used did not pro-
vide a satisfactory control for such effects, but the statis-
tical measures, that is, analysis of interaction between
treatment order and test session on outcome measure,
that were taken to address this issue confirmed the possi-
bility of placebo and training effects. Indeed, the WCST
has been shown to be sensitive to training effects (see, for
example, [35]) and should be used with care. Ideally, a
test less sensitive to training and with higher test-retest
reliability may be advisable for future studies, as well as a
pre-testing cognitive training session (before the baseline
assessment) in order to control for training artefacts.
Table 2 Results before, after four weeks of L-lysine treatment, and after four weeks of placebo treatment
Outcome measure Baseline Post L-lysine Post placebo F value P-value*
L-lysine blood conc (μmol/l) 196 ± 14 (201 ± 15) 401 ± 74 (363 ± 64) 195 ± 13 (195 ± 10) 7.84 (6.57) 0.024 (0.027)
Symptom severity scales
PANSS
Positive symptoms 14.6 ± 0.7 (16.0 ± 1.1) 11.9 ± 0.6 (13.5 ± 1.3) 11.6 ± 0.8 (13.4 ± 1.4) 13.11 (12.49) 0.001 (0.000)
Negative symptoms 18.4 ± 2.4 (19.7 ± 2.2) 17.4 ± 2.2 (19.4 ± 2.2) 17.3 ± 2.4 (18.8 ± 2.2) 1.53 (0.69) 0.25 (0.51)
General symptoms 31.3 ± 2.5 (33.5 ± 2.5) 29.5 ± 1.9 (32.3 ± 2.4) 29.1 ± 2.0 (30.9 ± 2.0) 2.14 (2.84) 0.16 (0.09)
Total 64.3 ± 4.2 (69.2 ± 4.7) 58.8 ± 4.0 (65.2 ± 5.4) 58.0 ± 4.5 (63.1 ± 5.0) 13.36 (8.59) 0.001 (0.002)
GAF 43.8 ± 1.8 (42.0 ± 1.9) 46.9 ± 1.6 (45.8 ± 1.6) 44.1 ± 2.3 (42.8 ± 2.1) 4.29 (7.34) 0.035 (0.005)
CGI 3.63 ± 0.18 (3.80 ± 0.20) 3.63 ± 0.18 (3.80 ± 0.20) 3.50 ± 0.27 (3.70 ± 0.26) 1.00 (1.00) 0.39 (0.39)
Depression scale
MADRS 8.50 ± 2.09 (9.10 ± 1.74) 7.50 ± 1.90 (7.90 ± 1.57) 8.38 ± 1.74 (8.40 ± 1.38) 0.54 (0.89) 0.59 (0.43)
Cognitive tests
RAVLT 45.9 ± 4.3 (43.5 ± 4.2) 46.0 ± 4.6 (43.3 ± 4.4) 48.8 ± 3.5 (45.2 ± 4.1) 0.79 (0.48) 0.47 (0.62)
CPT 0.76 ± 0.16 (0.67 ± 0.13) 0.81 ± 0.13 (0.76 ± 0.12) 0.86 ± 0.13 (0.71 ± 0.14) 0.25 (0.21) 0.77 (0.81)
Trail Making Test A 33.8 ± 1.7 (39.2 ± 5.9) 31.3 ± 2.5 (39.9 ± 8.9) 35.3 ± 4.5 (40.8 ± 6.3) 0.44 (0.07) 0.58 (0.93)
Trail Making Test B 77.4 ± 7.2 (134 ± 56) 70.0 ± 5.2 (119 ± 48) 71.3 ± 6.4 (124 ± 50) 0.40 (1.61) 0.68 (0.24)
Letter and number span 8.13 ± 0.90 (7.00 ± 1.03) 9.00 ± 0.66 (8.10 ± 0.82) 9.13 ± 0.92 (8.50 ± 0.95) 0.74 (1.92) 0.50 (0.18)
Wisconsin Card Sorting
Number of errors 33.9 ± 10.0 (31.9 ± 9.0) 21.0 ± 7.2 (19.7 ± 6.5) 24.4 ± 10.1 (23.2 ± 9.0) 4.91 (5.45) 0.024 (0.016)
Perseverant errors 20.4 ± 7.6 (19.0 ± 6.8) 11.5 ± 5.0 (10.7 ± 4.4) 14.8 ± 8.1 (13.4 ± 7.3) 4.46 (5.00) 0.032 (0.021)
Perseverant answers 23.6 ± 9.6 (21.9 ± 8.7) 13.1 ± 6.6 (21.1 ± 5.9) 17.1 ± 10.3 (15.6 ± 9.2) 4.77 (5.20) 0.026 (0.018)
Mean values outside parenthesis refers to analysis including individuals who did display an increase in blood levels of L-lysine during the L-lysine treatment
period (n = 8). Mean values within parenthesis refer to statistical analysis performed on all individuals, that is, also those not displaying increased blood levels of
L-lysine during the L-lysine treatment period (total n = 10). *Corrected by the Huynh-Feldt procedure as required.
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in a stable phase of their illness and were all treated
with atypical antipsychotics may also have made it more
difficult to detect beneficial effects of L-lysine treatment
on cognitive functioning and symptom severity. In this
respect, special attention may be paid to the self-
reported improvements of positive symptoms, attention
and memory capacity by three of the patients, since
these potential effects of the treatment would be impor-
tant but unfortunately could not be addressed by statis-
tical analysis. It should also be noted that the patient
who experienced improved memory capacity continu-
ously trained his memory using a computerized training
program.
There is an ongoing debate in the literature as to how
to disentangle training effects of repeated cognitive test-
ing, from “real” drug effects, as well as how to establish
consensus regarding a reliable cognitive test battery
[36-38]. The cognitive tests chosen for the purpose of
the present study are some of the most frequently
applied in research and several of them have been
shown to be resistant to training effects [39,40]. The
initiatives taken to pharmacologically enhance cognition
a r ep l e n t i f u l ;h o w e v e r ,t h er e s u l t so fs u c hs t u d i e sa r e
diverse and few studies have been able to demonstrate
replicable cognitive enhancement in patients with schi-
zophrenia [38]. One contributing factor to these short-
comings, may be that schizophrenia encompasses
abnormal progressive loss in brain volume [41], possibly
counteracting any cognitive enhancing potential. How-
ever, cognitive enhancing therapy was recently demon-
strated to counteract gray matter loss in patients with
schizophrenia [42].
Cognition is a highly specific and complex phenom-
enon that develops from early life into adulthood,
depending on both biological pre-disposition as well as
environmental input [36]. Perhaps the lack of develop-
ment of cognitive enhancing agents is due to an overly
optimistic belief in cognitive enhancement being viable
without concurrent cognitive training. The plasticity of
the brain is a complex, time- and stimulus-dependent
process by which the strengthening of synapses has to
be modulated in order for learning to occur [43]. Thus,
it may in fact not be possible to find improvements in
cognition by solely adding cognitive enhancing com-
pounds without simultaneous cognitive training. There-
fore, it is interesting that L-lysine treatment in
combination with training was perceived to improve
memory capacity in one patient. Moreover, adjunctive
L-lysine treatment needs to be investigated in a larger
placebo-controlled, double-blinded study further limiting
possible training effects.
Taken together, preclinical and clinical studies have
provided evidence for the involvement of a brain NO
imbalance in schizophrenia. Furthermore, preliminary in
vivo studies in rats have indicated that NO production
is decreased by L-lysine [26]. Consequently, L-lysine
may have a beneficial potential in the treatment of the
disorder. In addition, targeting the NO pathway may
represent a new therapeutic approach that is pharmaco-
logically fundamentally different from that of the tradi-
tional antipsychotics and, hence, may be beneficial in
targeting symptoms that are currently treatment
resistant.
Conclusions
To our knowledge, the present study is the first to
investigate L-lysine treatment as a potential new add-on
treatment for patients with schizophrenia, and as a
novel means of targeting the NO pathway in order to
treat a psychiatric disorder.
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